New Delhi: The subject expert committee of the Central Drugs Standard Organization has recommended approval of ZyCoV-D, the vaccine manufactured by Ahmedabad-based pharma giant Zydus Cadila. It has recommended that the vaccine be given emergency use authorization (EAU), said CNBC-TV18, quoting sources. The recommendation has been sent to the Drug Controller General of India (DCGI).
The company had applied for authorization of the vaccine on July 1, citing an efficacy rate of 66.6% in a late-stage trial of over 28,000 volunteers across the country.
The committee had met on Thursday.
The approval for use would make ZyCoV-D the fifth vaccine to be cleared for use in India. Others that are allowed to be administered in the country are Covishield, Covaxin, Sputnik V and Moderna.
The vaccine by Zydus Cadila will also become the first DNA vaccine in the world to get clearance in any country. It is also the second indigenously made Covid vaccine after Covaxin.
ZyCoV-D is an intra-dermal vaccine that can be administered without a syringe. It can be stored at a normal refrigeration temperature of 2-8 degrees.
The subject expert committee is of the opinion that Zydus Cadila must submit additional data for the two-dose vaccine.
To read the latest news in Gujarati click here